Point72 Asset Management, L.P. 13D and 13G filings for Inhibikase Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
2025-02-14 4:08 pm Sale |
2024-12-31 | 13G | Inhibikase Therapeutics, Inc. IKT |
Point72 Asset Management, L.P. | 0 0.000% |
-625,000![]() (Position Closed) |
Filing |
2024-10-10 4:10 pm Purchase |
2024-10-09 | 13G | Inhibikase Therapeutics, Inc. IKT |
Point72 Asset Management, L.P. | 625,000 8.400% |
625,000![]() (New Position) |
Filing |